Cost-Effective HIV PrEP: CAB-LA Transforms Prev...

By Rene Pretorius

April 16, 2025

Summary Cabotegravir long-acting (CAB-LA) delivers a cost-effective HIV PrEP solution. It reduces infections and supports the Ending the HIV Epidemic (EHE) initiative. This review exami...
Advancing Early Childhood Health: PureHealth’s Partnership with Abu Dha...
Toripalimab Evidence Journey in Cancer Care
NICE Breakthrough: Record Positive Recommendations for Blood Cancer Treatment...
Approval of Pembrolizumab Enfortumab Therapy: Insights on Efficacy, Costs, an...
Cancer Control Month 2025: Key Takeaways from President Trump’s National Call...
Oral Cancer in East Africa: The Need for Early Detection
Engineering Resilience: Mastering Pharma Patent Expiration Strategy
Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefit...
Oral Health in Africa: Promoting Collaborative Solutions
Advances in Colorectal Cancer Screening: Access and Cost
Systems Thinking in Pharmaceutical Access: Future-Proofing Value Strategy
HIV Colorectal Cancer Survival